Bernstein Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $32
New hope for bladder cancer! Pfizer (PFE.US) immunotherapy's key phase 3 trial has reached its primary endpoint.
Pfizer (PFE.US) announced today that its PD-1 targeting monoclonal antibody sasanlimab has reached the primary endpoint in the pivotal Phase 3 CREST trial.
Pfizer Options Spot-On: On January 10th, 114.74K Contracts Were Traded, With 3.27 Million Open Interest
Weekly Buzz: CES Came and Brought the Pain? That's Unexpected
Wall Street Today: Labor Gains Hurt a Hurting Market
BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst
